Twin Capital Management Inc. Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Twin Capital Management Inc. bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 4th quarter, HoldingsChannel reports. The firm bought 2,208 shares of the biopharmaceutical company’s stock, valued at approximately $878,000.

Other hedge funds also recently bought and sold shares of the company. Root Financial Partners LLC acquired a new stake in Alnylam Pharmaceuticals in the third quarter worth $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in Alnylam Pharmaceuticals in the third quarter worth $29,000. Ameriflex Group Inc. acquired a new stake in Alnylam Pharmaceuticals in the third quarter worth $32,000. Aster Capital Management DIFC Ltd acquired a new stake in Alnylam Pharmaceuticals in the third quarter worth $36,000. Finally, Newbridge Financial Services Group Inc. acquired a new stake in Alnylam Pharmaceuticals in the third quarter worth $39,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Up 0.7%

Shares of ALNY stock opened at $300.51 on Friday. The firm’s fifty day moving average price is $311.62 and its two-hundred day moving average price is $359.92. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. Alnylam Pharmaceuticals, Inc. has a 1 year low of $284.19 and a 1 year high of $495.55. The firm has a market capitalization of $40.12 billion, a P/E ratio of 82.11 and a beta of 0.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. The company had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The company’s quarterly revenue was up 96.4% on a year-over-year basis. During the same period in the prior year, the business posted ($0.44) EPS. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Wells Fargo & Company increased their target price on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a report on Friday, May 1st. Citigroup started coverage on shares of Alnylam Pharmaceuticals in a research note on Tuesday. They issued a “buy” rating and a $380.00 target price for the company. Bank of America reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Canaccord Genuity Group upped their target price on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Finally, Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $463.13.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 6,799 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total value of $2,227,692.35. Following the completion of the transaction, the chief executive officer directly owned 98,628 shares of the company’s stock, valued at approximately $32,315,464.20. This trade represents a 6.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Melissa Mclaughlin sold 2,286 shares of the company’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the sale, the insider directly owned 9,443 shares in the company, valued at $3,120,156.06. This trade represents a 19.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 21,255 shares of company stock valued at $6,930,337 in the last ninety days. 0.86% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.